These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33384242)

  • 1. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence.
    Dixon DL; Saseen JJ
    J Am Pharm Assoc (2003); 2021; 61(3):e83-e85. PubMed ID: 33384242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of PCSK9 modulation on cardiovascular outcomes: recent advances and the managed care implications.
    Dixon DL
    Am J Manag Care; 2022 Sep; 28(8 Suppl):S139-S147. PubMed ID: 36493346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease.
    Dayoub EJ; Eberly LA; Nathan AS; Khatana SAM; Adusumalli S; Navar AM; Giri J; Groeneveld PW
    J Am Heart Assoc; 2021 May; 10(9):e019331. PubMed ID: 33904340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managed care pharmacist updates for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Patel J
    Am J Manag Care; 2021 Mar; 27(4 Suppl):S76-S82. PubMed ID: 33710847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
    Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
    Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD.
    Talasaz AH; Ho AJ; Bhatty F; Koenig RA; Dixon DL; Baker WL; Van Tassell BW
    Pharmacotherapy; 2021 Dec; 41(12):1009-1023. PubMed ID: 34657313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein convertase subtilisin/kexin type 9 inhibition in cardiovascular disease: current status and future perspectives.
    Cho KH; Hong YJ
    Korean J Intern Med; 2020 Sep; 35(5):1045-1058. PubMed ID: 32921006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
    Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
    Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.